专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060199782A1 Compositions and methods for therapeutic use 失效
标题翻译：用于治疗用途的组合物和方法
公开(公告)号：US20060199782A1
公开(公告)日：2006-09-07
申请号：US11359997
申请日：2006-02-21
申请人： Heidrun Engler , Tattanahalli Nagabhushan , Stephen Youngster
发明人： Heidrun Engler , Tattanahalli Nagabhushan , Stephen Youngster
IPC分类号： A61K48/00 , A61K31/704 , A61K31/56
CPC分类号： A61K48/00
摘要： A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
摘要翻译：一种用于增强治疗剂转移至细胞的方法和药物组合物，其中所述治疗剂配制在包含式I化合物的缓冲液中：其中：n为2-8的整数; X 1是胆酸基或脱氧胆酸基; X 2和X 3各自独立地选自胆酸基，脱氧胆酸基和糖基，其中选择糖基团从戊糖单糖组，己糖单糖组，戊糖 - 戊糖二糖基团，己糖 - 六糖基团，戊糖 - 六糖二糖基团和己糖 - 戊糖二糖基团组成的组; 并且其中X 2和X 3中的至少一个是糖基团。

2. 发明授权

US5972331A Crystalline interferon alpha for pulmonary delivery and method for producing the same 失效
标题翻译：用于肺部输送的结晶干扰素α及其制备方法
公开(公告)号：US5972331A
公开(公告)日：1999-10-26
申请号：US577585
申请日：1995-12-22
申请人： Paul Reichert , Patricia C. Weber , Rowena F. Choudrie , Bruce O. Stuart , Tattanahalli Nagabhushan , Ashit Ganguly
发明人： Paul Reichert , Patricia C. Weber , Rowena F. Choudrie , Bruce O. Stuart , Tattanahalli Nagabhushan , Ashit Ganguly
IPC分类号： A61K9/00 , A61K9/16 , A61K38/00 , C07K14/56 , A61K45/05
CPC分类号： A61K9/0078 , A61K9/1688 , C07K14/56 , A61K38/00
摘要： A method to prepare crystalline interferon alpha suitable for aerosol formulation either for systemic or topical (inhaled) drug delivery. The bioavailable interferon is in the form of crystalline submicrometer particles having a predetermined medium diameter.
摘要翻译：制备用于全身或局部（吸入）药物递送的气溶胶制剂的结晶干扰素α的方法。生物可利用的干扰素是具有预定中等直径的结晶亚微米颗粒的形式。

3. 发明申请

US20050025742A1 Methods and compositions for interferon therapy 审中-公开
标题翻译：用于干扰素治疗的方法和组合物
公开(公告)号：US20050025742A1
公开(公告)日：2005-02-03
申请号：US10861654
申请日：2004-06-04
申请人： Heidrun Engler , Tattanahalli Nagabhushan , Stephen Youngster , Robert Connor
发明人： Heidrun Engler , Tattanahalli Nagabhushan , Stephen Youngster , Robert Connor
IPC分类号： A61K20060101 , A61K9/00 , A61K38/21 , A61K48/00
CPC分类号： A61K9/0034 , A61K38/21
摘要： Methods and pharmaceutical compositions for administering protein or gene therapy to tissues or organs having an epithelial cell layer are provided. A protein or nucleic acid encoding the protein is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the delivery of the interferon or nucleic acid to the cells of the target tissues or organs. The methods and combinations are particularly useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an alpha-interferon or a gene delivery system encoding the interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 10 to 1000 fold increased in interferon levels and activity may be observed with the use of a SYN3 formulation as opposed to a PBS formulation of the same interferon protein or interferon gene delivery system.
摘要翻译：提供了用于对具有上皮细胞层的组织或器官进行蛋白质或基因治疗的方法和药物组合物。将编码蛋白质的蛋白质或核酸与目标组织或器官联合施用递送增强剂的组合施用，所述递送增强剂增加干扰素或核酸向靶组织或器官的细胞递送。所述方法和组合在治疗癌症和其它对干扰素治疗有反应的病症方面特别有用。示例性方法包括向膀胱经尿道膀胱内施用治疗有效量的药物组合物，其包含α-干扰素或编码干扰素和SYN3或SYN3同源物或类似物的基因递送系统。在膀胱中，与使用相同干扰素蛋白或干扰素基因递送系统的PBS制剂相比，使用SYN3制剂可以观察到高达10至1000倍的干扰素水平和活性。

4. 发明授权

US6004549A Crystalline protein controlled release compositions 失效
标题翻译：结晶蛋白质控释组合物
公开(公告)号：US6004549A
公开(公告)日：1999-12-21
申请号：US355585
申请日：1994-12-14
申请人： Paul Reichert , Alan W. Hruza , Nagamani Nagabushan , Tattanahalli Nagabhushan
发明人： Paul Reichert , Alan W. Hruza , Nagamani Nagabushan , Tattanahalli Nagabhushan
IPC分类号： A61K9/00 , A61K38/00 , A61K38/21 , A61K38/28 , A61K47/10 , A61K47/44 , C07K14/56 , C07K14/00
CPC分类号： A61K47/44 , A61K38/212 , A61K38/28 , A61K47/10 , A61K9/0019 , C07K14/56
摘要： A pharmaceutical composition comprised of a crystalline protein and polyethylene glycol or vegetable oil and a process for producing the same.
摘要翻译：由结晶蛋白质和聚乙二醇或植物油组成的药物组合物及其制造方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式